Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Mediwound (MDWD – Research Report), retaining the price target of $30.00.
Michael Okunewitch has given his Buy rating due to a combination of factors that highlight Mediwound’s promising future prospects. The company has reported a solid financial position with $43.6 million in cash, which is expected to sustain operations until 2027. This financial stability is crucial as Mediwound embarks on significant projects, including the pivotal Phase 3 study for EscharEx, which targets the substantial $2.5 billion chronic wound care market. The interim results for this study are anticipated in mid-2026, with further studies planned to enhance its market potential.
Additionally, Mediwound’s NexoBrid manufacturing facility is now complete, and the company is seeking regulatory approvals in both the EU and US, expected in early 2026. The revenue guidance for 2025 has been adjusted to $24 million to $26 million, with growth driven by pricing and geographic shifts. The company’s strategic focus on expanding its product offerings and improving its manufacturing capabilities positions it well for future revenue growth, particularly with EscharEx’s potential to outperform existing market leaders. These factors collectively underpin Okunewitch’s optimistic outlook and Buy rating for Mediwound’s stock.
In another report released yesterday, Craig-Hallum also initiated coverage with a Buy rating on the stock with a $39.00 price target.